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Ocular Melanoma
Harika Regani and Santosh G. Honavar
Abstract
Ocular melanoma is the most common malignant tumor in adults after cutane-
ous melanoma. There is a wide clinical spectrum depending upon the location of the
tumor. The various predispositions, risk factors, tumor classification, and treatment
modalities are discussed. Choroidal melanoma is the most common type of ocular
melanoma. Its management has evolved over the years. The Collaborative Ocular
Melanoma Study (COMS) has helped to precisely classify choroidal melanoma and
standardize its treatment. The future lies in the genetics which can help prognosti-
cate and provide adjuvant treatment to patients at risk.
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1. Introduction
The incidence of melanoma continues to rise globally with significant mortality
in spite of modern treatment protocols [1]. Ocular melanoma is the most common
type of melanoma in adults after the cutaneous melanoma. It constitutes 3.7% of all
melanomas [2]. It results due to the abnormal proliferation of the melanocytes in
the eye. Based on the location, the ocular melanoma can be broadly classified as
follows:
1.Eyelid melanoma
2.Conjunctival melanoma
3.Uveal melanoma
a. Iris melanoma
b. Trabecular meshwork melanoma
c. Iridotrabeculociliary or iridociliary melanoma
d. Ciliary body melanoma
e. Choroidal melanoma
f. Ciliochoroidal melanoma
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2. Eyelid melanoma
Eyelid melanoma is relatively and comprises less than 1% of all eyelid cancers.
Serial documentation and close monitoring of suspicious lesions play a very impor-
tant role in early diagnosis. Variable pigmentation, rapid increase in size, change in
color, abnormal vascularity, and tendency to bleed are the typical features of eyelid
melanoma [3].
3. Conjunctival melanoma
3.1 Epidemiology
The clinical spectrum of melanocytic tumors of the conjunctiva constitutes
about 53% of all conjunctival tumors. The reported incidence is two cases per
million per year, but the incidence is increasing. It usually occurs at a median age of
62 years and is very rare in children [4, 5].
3.2 Risk factors
1.PAM: 22% (overall: 9%, with atypia: 13%, and without atypia: 0%)
2.Preexisting nevus in 15%
3.De novo 5% [6, 7]
4.Dysplastic nevus syndrome
5.Neurofibromatosis
6.Xeroderma pigmentosum [8]
3.3 Clinical presentation
1.Fleshy, variably pigmented (tan to dark brown) placoid, or modular elevated
lesion located on the limbal, bulbar, forniceal, or palpebral conjunctiva. The
lesions which are localized, bulbar, thin, and limbal have a good prognosis
where as those which are large, diffuse, forniceal, on caruncle and tarsus have
poorer prognosis (Figure 1).
2.Prominent feeder vessels (conjunctival and scleral)
3. It can develop secondarily in contiguity with an eyelid margin which is called
as implantation melanoma [9].
3.4 Treatment
1.A careful dissection of the mass with “no-touch technique,”wide excision with
frozen section margin control is ideal.
2.Alcohol keratoepitheliectomy for the corneal involvement.
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3.Double freeze thaw cryotherapy of the resection edge and the clinically
suspected involved base if it is less than 3 clock hours.
4.Episcleral plaque brachytherapy if base is involved for more than 3 clock
hours. Plaque rotation can be customized depending on the tumor extent.
5. Interferon and interleukin-2 in combination can be administered in
disseminated melanoma [8].
6.Sentinel lymphangiography is indicated in tumors more than 2 mm and helps
in complete removal of the lymph nodes.
3.5 Histopathology
Abnormal proliferation of the melanocytes, spindle, or the epitheloid cells.
3.6 Prognosis
1.Metastasis to ipsilateral facial lymph nodes, brain, lung, skin, bone, and liver
are the most common.
2.Multiple recurrences, especially those within the orbit, might require orbital
exenteration [4].
3. Intraocular and intraorbital involvement may require modified enucleation
and orbital exenteration, respectively.
4.Recurrences after the therapy are 50–70% at 10 years.
5.Overall mortality rate is 25% at 10 years and more than 30% in 15 years [9, 10].
6.The 10 year rate of metastasis is PAM 25%, Nevus 26%, De novo 49% [11]
7.The prognosis can be predicted by the AJCC-TNM staging of conjunctival
melanoma (Table 1).
8.The factors predictive of metastasis or death are de novo origin, tarsal or
forniceal location, nodular mass, and orbital invasion [11].
Figure 1.
Conjunctival melanoma.
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3.7 Newer innovations
1.Pembrolizumab—for recurrent conjunctival tumors [12]
2.Nivolumab [13]
4. Uveal melanoma
It is the most common primary intraocular malignancy in adults. The earlier
detection and prompt treatment has decreased the morbidity to some extent over
the years.
Definition of primary clinical tumor (cT)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor of the bulbar conjunctiva
T1a < 1 quadrant
T1b > 1 but <2 quadrants
T1c > 2 but <3 quadrants
T2 Tumor of nonbulbar conjunctiva (forniceal, palpebral, tarsal, caruncle)
T2a Noncaruncular and < 1 quadrant nonbulbar conjunctiva
T2b Noncaruncular and > 1 quadrant nonbulbar conjunctiva
T2c Caruncular and < 1 quadrant nonbulbar conjunctiva
T2d Caruncular and > 1 quadrant nonbulbar conjunctiva
T3 Tumor of any size with local invasion
T3a Globe
T3b Eyelid
T3c Orbit
T3d Nasolacrimal duct and/or lacrimal sac and/or paranasal sinuses
T4 Tumor of any size with invasion of central nervous system.
Definition of regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
N0 Regional lymph node metastasis absent
N1 Regional lymph node metastasis present
Definition of distant metastasis (M)
M0 Distant metastasis absent
M1 Distant metastasis present
Definition of primary pathological tumor (pT)
TX Primary tumor cannot be assessed
T0 No evidence or primary tumor
Tis Tumor confined to conjunctival epithelium
T1 Tumor of bulbar conjunctiva
T1a Tumor with <2 mm thickness invasion of substantia propria
T1b Tumor with >2 mm thickness invasion of substantia propria
T2 Tumor of nonbulbar conjunctiva
T2a Tumor with <2 mm thickness invasion of substantia propria
T2b Tumor with >2 mm thickness invasion of substantia propria
T3 Tumor of any size with local invasion
T3a Globe
T3b Eyelid
T3c Orbit
T3d Nasolacrimal duct and/or lacrimal sac and/or paranasal sinuses
T4 Tumor of any size with invasion of central nervous system
Table 1.
AJCC 8th edition classification of conjunctival melanoma.
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Based on the location, they can be classified into
a. Iris melanoma
b. Trabecular meshwork melanoma
c. Iridotrabeculociliary or iridociliary melanoma
d. Ciliary body melanoma
e. Choroidal melanoma
f. Ciliochoroidal melanoma
The most common differential diagnosis of uveal melanoma is anevus. The
following are the key points to differentiate the two (pneumonic: ABCDEF):
1.Age ≤ 40 years
2.Blood vessels
3.Clock hours inferiorly
4.Diffuse configuration
5.Ectropion uveae
6.Feathery margin
4.1 Iris melanoma
4.1.1 Epidemiology
Iris melanoma constitutes about 4% of uveal melanomas [14]. The mean age at
presentation is 40–47 years. It is very rarely seen in the pediatric age group. Males and
females are equally affected. It is most commonly seen in Caucasians (97.8%) [15].
4.1.2 Clinical presentation
Nodular pigmented lesionusually seen in the inferior iris. It is usually associatedwith
tumor seeding in the adjacent iris or trabecularmeshwork and secondary glaucoma.
4.1.3 Types
1.Circumscribed
2.Diffuse
4.1.4 Management
1.Observation of clinically suspicious lesions
2.Local resection (iridectomy/iridocyclectomy) for tumors less than 3–4 clock hours
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3.Plaque brachytherapy—has up to 87% chance if tumor control after local
resection
4.Proton beam therapy
5.Enucleation—for diffuse, recurrent tumors or eyes with intractable glaucoma
4.1.5 Differential diagnosis
1.Primary iris cyst
2.Iris nevus
3.Essential iris atrophy
4.Iris foreign body
5.Peripheral anterior synechiae
6.Iris metastasis
4.1.6 Factors predictive of metastasis
1.Increased age at diagnosis [16, 17]
2.Angle invasion
3.Elevated intraocular pressure
4.Extraocular extension
5.Previous surgical intervention before referral prognosis [14]
Prognosis is better than ciliary body or choroidal melanoma with a 10-year
metastasis of 7% as compared to 25% in choroidal melanoma and 34% for ciliary
body melanoma.
4.2 Ciliary body melanoma
It is relatively a rare uveal tumor and is reported in one of 10 cases of all
intraocular melanomas [18, 19].
4.2.1 Clinical presentation
1.Diminution of vision due to astigmatism or lens dislocation
2.Painless visual field loss or pain due to acute glaucoma
3.Episcleral sentinel vessels
4.Unexplained relatively low intraocular pressure
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Management options include local resection, plaque brachytherapy, proton
beam radiation, and enucleation.
4.2.2 Histopathological types (callender classification)
1.Spindle A and B type melanoma—best prognosis
2.Mixed cell melanoma
3.Epitheloid cell melanoma—poor prognosis
4.Necrotic melanoma—poor prognosis
4.2.3 Metastasis
Hematogenous metastasis is faster in ciliary body melanoma as a result of
continuous contractions of the ciliary muscle and rich vascularization.
T Category and criteria
T1—Tumor limited to the iris
T1a—Tumor limited to the iris, not more than 3 clock hours in size
T1b—Tumor limited to the iris, more than 3 clock hours in size
T1c—Tumor limited to the iris with secondary glaucoma
T2—Tumor confluent with or extending into the ciliary body, choroid, or both
T2a—Tumor confluent with or extending into the ciliary body, without secondary glaucoma
T2b—Tumor confluent with or extending into the ciliary body and choroid, without secondary
glaucoma
T2c—Tumor confluent with or extending into the ciliary body, choroid, or both with secondary
glaucoma
T3—Tumor confluent with or extending into the ciliary body, choroid, or both, with scleral extension
T4—Tumor with extrascleral extension
T4a—Tumor with extrascleral extension ≤5 mm in largest diameter
T4b—Tumor with extrascleral extension >5 mm in largest diameter
G Category and criteria
GX—Grade cannot be assessed
G1—Spindle cell melanoma (>90% spindle cells)
G2—Mixed cell melanoma (>10% epitheloid cells and < 90% spindle cells)
G3—Epitheloid cell melanoma (>90% epitheloid cells)
N Category and criteria
N1—Regional lymph node metastasis or discrete tumor deposits in the orbit
N1a—Metastasis in one or more regional lymph node(s)
N1b—No regional lymph nodes are positive, but there are discrete tumor deposits in the orbit that
are not contiguous to the eye
M Category and criteria
M0—No distant metastasis by clinical classification
M1—Distant metastasis
M1a—Largest diameter of the largest metastasis ≤3 cm
M1b—Largest diameter of the largest metastasis 3.1–8 cm
M1c—Largest diameter of the largest metastasis ≥8.1 cm
Table 2.
AJCC 8th edition classification of iris melanoma [20].
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4.2.4 Prognosis
The prognostic factors are listed in Table 3.
4.3 Choroidal melanoma
Choroidal melanoma is the most common uveal melanoma and constitutes about
90% of all uveal melanomas. This is usually seen in an elderly age group at around
60 years and there is no gross gender predilection. It is seen predominantly in
Caucasians (98%), as compared to other races. It has a pronounced tendency to
metastasize resulting in high mortality [21]. Predisposing factors are listed in
Table 4.
4.3.1 Clinical presentation
It can be incidentally detected in asymptomatic patients on routine ocular
examination. Most of the patients, however, manifest with diminution of vision,
floaters, photopsia, visual field loss, or pain due to impingement of posterior ciliary
nerve or angle closure glaucoma. It can metastasize to liver (89%), lung (29%), and
bone (17%). Median survival after metastasis is 6–12 months [22]. Males have a
poor prognosis than females. The lower metastatic rate in females can be explained
due to the inhibitory action of estrogen on the growth of micrometastases within
the liver [23, 24].
4.3.2 Classification
Choroidal melanoma can be broadly classified into diffuse (Figure 2) and
circumscribed (Figure 3). The circumscribed variant can either be dome-shaped
(75%) or mushroom-shaped (20%). Diffuse choroidal melanoma is seen in 3–17%
cases and has a substantial risk of metastasis despite its flat appearance. The poor
prognostic factors include delayed diagnosis, greater proportion of epitheloid cells,
and a tendency for extraocular extension [25].
AJCC Classification has already been mentioned under the section of iris
melanoma (Table 2).
Clinical Macroscopic Microscopic
Local/general signs
Local extension
Presence of metastasis
Age of the patient
Dysplastic nevi
Size of the tumor
<11 mm—small
11–15 mm—medium
>15 mm—large
Epitheloid and necrotic cellular patterns
Necrosis
Intense pigmentation
Melanophagic, lymphocytic infiltrate
Table 3.
The prognostic factors for ciliary body melanoma.
Host factors Environment factors
Light colored eyes
Fair skinned
Intermittent ultraviolet exposure to arc welding
Chronic UV exposure
Occupational sunlight exposure
Table 4.
Predisposing factors.
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The most common precursor lesion for choroidal melanoma is the preexisting
choroidal nevus (Figure 4), followed by oculodermal melanocytosis.
The following are used to differentiate a choroidal nevus from a melanoma
(pneumonic: to find small ocular melanoma using helpful hints daily):
1.Thickness > 2 mm
2.Fluid
Figure 2.
Diffuse choroidal melanoma.
Figure 3.
Circumscribed choroidal melanoma.
Figure 4.
Choroidal nevus.
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3.Symptoms
4.Orange pigmentation
5.Margin <3 mm to disk
6.Ultrasound hollow
7.Absent halo
8.Absent grusen
4.3.3 Investigations
4.3.3.1. Ultrasonography
It has 95% accuracy and is useful to estimate tumor size for periodic observation
and to evaluate for extraocular extension.
The characteristic features on A-scan are:
1. Initial prominent spike
2.Low to medium internal reflectivity with diminishing amplitude
3.Fine oscillation of internal spiking pattern (vascular pulsations)
The characteristic features on B-scan are:
1.Low to medium internal reflectivity
2.Choroidal excavation
3.Shadowing of subadjacent soft tissue
4.Internal vascularity
5.Acoustic hallowing
4.3.3.2. Autofloroscence
Hyperautofluorescence of orange-colored lipofuscin pigment.
4.3.3.3. Fundus fluorescein angiography
Small melanoma: Hypofluorescence (blocked fluorescence)
Large melanoma: Patchy pattern of early hypofluorescence and hyperfluorescence
followed by late intense staining. Double circulation—internal vascularity
4.3.3.4. Ultrasound biomicroscopy
It helps to differentiate anterior tumors from those of ciliary body origin.
Although the tumor margins and extent is well delineated by UBM, the resolution of
internal tumor details is limited.
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4.3.3.5. Optical coherence tomography
Dome-shaped choroidal mass with overlying outer retinal thickening and
subretinal fluid.
Optical coherence tomography angiography shows reduced capillary density in
the affected eye.
4.3.3.6. Magnetic resonance imaging
Pigmented melanomas can be seen as T1 Hyperdense and T2 hypodense
intraocular masses.
4.3.3.7. Fine needle aspiration cytology
Although reliable, it is technically challenging and requires expertise.
4.3.4 Management
The most common treatment modality is the episceral plaque brachytherapy.
Plaque brachytherapy is suitable for tumors up to 16 mm in diameter and up to
6 mm thickness with Ruthenium-106 and up to 8 mm thickness with Iodine-125.
The dose to the tumor apex should be 10,000 cGy and almost up to 90% tumor
control can be achieved. Enucleation is an option for tumors beyond the scope of
plaque brachytherapy. Orbital exenteration might be required in tumors with
orbital invasion. The proton beam irradiation has a higher chance of eye salvage but
the availability and affordability are the considerable limitations. The other treat-
ment modalities include laser photocoagulation, transpupillary thermotherapy,
chemotherapy, and immunotherapy.
The various newer treatment modalities under evaluation are:
1.Chemotherapy with dacarbazine+interferon alpha, cisplatin, tamoxifen
+sunitinib, and fotemustine.
2.Targeted therapy with crizotinib, sunitinib, and valproic acid.
3. Immunotherapy with Ipilimumab with nivolumab.
4.3.5 Histopathology
Modified Callenders’s classification describes various patterns on
histopathology.
1.Spindle cell nevi
2.Spindle cell melanoma
3.Necrotic melanoma
4.Epitheloid cell melanoma
5.Mixed cell melanoma
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The epitheloid cell and the mixed cell melanoma have the poorest prognosis
among all the subtypes (Table 5). Immunohistochemical markers characteristic of
choroidal melanoma are S-100, HMB-45.
4.3.6 Metastasis
The risk factors for metastasis include (Table 7):
1.Thickness > 2 mm
2.Symptoms
3.Margin <3 mm to disk
4.Documented growth
The presence of four risk factors has a metastatic rate of 20% but the absence of
risk factors has only <1% risk of systemic metastasis. Also, each millimeter increase
in thickness adds 5% risk for metastasis at 10 years and a hazard ratio of 1.08 [27].
Doubling time of untreated metastases ranged from 34 to 220 days (median,
63 days). The metastasis from tumors as small as 3 3 1.5 mm has been noted in a
study [28]. Based on the estimated growth rates, a rational follow-up interval to
detect metastatic uveal melanoma would be 4–6 months. Primary uveal melanomas
that develop clinically detectable metastasis after conservative therapy may have
micrometastasized several years before treatment.
Damato’s classification of metastasis [26]:
1.Metastasizing melanomas, which have already metastasized by the time of
ocular treatment even though the metastases may not be detectable.
Clinical features Histopathologic features Cytogenetic features Transcriptomic
feature
Older age at presentation Epithelioid cytology Chromosome 3 loss
(monosomy 3)
Gene expression
profile class 2
Male gender High mitotic activity/PC-10/
Ki-67
Chromosome 8q gain
or 8p loss
Larger tumor basal
diameter
High values of mean diameter
of 10 largest nucleoli
Chromosome 1p loss
Thicker tumor High microvascular density Chromosome 6q loss
Ciliary body tumor location Microvascular loops and
patterns
Chromosome 9q loss
Diffuse tumor
configuration
Tumor-infiltrating
lymphocytes, macrophages
BAP1 loss
Association with ocular/
oculodermal melanocytosis
Loss of nuclear
immunostaining for BAP1
Extraocular tumor
extension
High expression of insulin-
like growth factor 1 receptor
Advanced AJCC category
and staging
High expression of HLA class
I and II
Table 5.
The poor prognostic factors include [26].
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2.Pre-metastasizing melanomas, which develop metastatic capability and
disseminate if treatment is delayed.
3.Non-metastasizing melanomas, which do not metastasize even if never treated.
4.3.7 Colloborative ocular melanoma study
This is the largest study ever to be performed in Ocular oncology with 43
participating centers and more than 2000 patients [29, 30].
Objectives of the study:
1.To evaluate the therapeutic interventions for patients with choroidal
melanoma
2.To determine which of the two, enucleation or brachytherapy prolongs the
lifetime of an individual, and if both have a similar survival, then which offers
the longer cancer-free survival and better prognosis for vision.
Inclusion and exclusion criteria:
• Primary choroidal melanoma in one eye
• Less than 50% involvement of ciliary body
• Age 21 years or older
• Ability to give informed consent
• Ability to return for treatment and scheduled follow-up
• No primary cancer (except noninvasive nonmelanotic skin cancer/CIS cervix)
• No coexisting disease threatening survival (5 years or longer)
• No metastatic melanoma
• No contraindication for surgery/RT
• No previous FNAB
• No previous treatment
• No extrascleral extension of 2 mm or more
• No diffuse, ring or multifocal tumor
• No iris/angle involvement
• No use of immunosuppressive therapy that cannot be discontinued
Outcome measures:
1.Primary outcome: Time to death from all-cause mortality
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2.Secondary outcome: Metastasis-free survival, cancer-free survival, and years
of useful vision
Trial design and treatment groups:
1.Small <3 (1.5–2.4) mm, 5 mm (observational group)
2.Medium 3–8 (2.5–10) mm, 16 mm (randomized group)
3.Large >8 (10 mm), >16 mm (randomized group)
Results:
1.Pre-enucleation EBRT for large melanoma has no advantage over enucleation
group. Five-year Kaplan–Meier estimates for survival were 57% for the
enucleation group and 62% for the pre enucleation radiation group.
2.Enucleation versus brachytherapy for medium melanoma were comparable.
The cumulative all-cause mortality at 12 years was 43% for patient in the
plaque radiotherapy group versus 41% for those in enucleation group.
3.The small tumor trial showed that small choroidal melanomas managed by
observation showed tumor growth in 21% by 2 years and 31% by 5 years.
Observation for small melanoma is not acceptable now and is treated
appropriately.
4.3.8 Genetic markers
The mitogen-activated protein kinase (MAPK) pathway is one of the main
regulatory pathways involved in choroidal melanoma development, particularly
through mutations in BRAF, NRAS, and KIT. Choroidal melanoma with BRAF
mutation is common in younger patients and the ones associated with preexisting
nevi. KIT mutations are the least common choroidal melanoma mutation in MAPK
pathway. NRAS mutation is very rare in choroidal melanoma [21–33]. Disomy 3 and
chromosome 6p gain are associated with a good prognosis.
Chromosome 3 loss, 8q gain, 1p loss and 6q loss = Class 1 associated with poor
prognosis.
Based on gene expression prolifes (GEP), uveal melanoma is now classified into
three prognostic categories for metastasis (Table 6).
The GEPs are playing a major role at present in prognosticating the risk of
metastasis. The tumor as such is constantly evolving at the genetic and molecular
level which is described as intratumoral genetic heterogeneity. The term cresendo
malignancy is described which explains the transformation of a small tumor which
is slow growing over years but acquires Class 2 genetic changes over time (Table 6).
Systemic metastasis at 5 years
Class 1A Low risk 2%
Class 1B Intermediate risk 21%
Class 2 High risk 72%
Table 6.
Prognostic categories for metastasis.
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4.3.9 Follow-up
A periodic follow-up with systemic investigations is mandatory in view of high
metastatic rates of choroidal melanoma. An annual PET-CT scan is ideal, however,
the monitoring of the liver function tests, ultrasonography of the abdomen and the
chest X-Ray are reasonably good.
5. Conclusion
Ocular melanoma is being effectively managed currently. A protocol-based
management of the patient can lead to good local tumor control and careful sys-
temic monitoring can decrease the morbidity and mortality to a great extent. The
ongoing research in genetics will probably help us understand and prognosticate
ocular melanoma in a better way.
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Tumor size Monosomy 3 If M3, metastasis by 3 years
Small 0–3 mm 23% 0%
Med 3–8 mm 35% 24%
Large >8 mm >50% 58%
Table 7.
Metastasis depends on several factors: Size, markers-BAPI, and genetics [34].
15
Ocular Melanoma
DOI: http://dx.doi.org/10.5772/intechopen.93760
References
[1] GLOBOCAN 2012 v1.0, Cancer
Incidence and Mortality Worldwide:
IARC Cancer Base No. 11 [Internet].
2013 [Cited: April 6, 2017]. Available
from: http://globocan.iarc.fr. [Accessed:
26 July 2020]
[2]McLaughlin CC, Wu XC, Jemal A,
Martin HJ, Ro-Che LM, Chen VW.
Incidence of noncutaneous melanomas
in the U.S. Cancer. 2005;103:1000-1007
[3] Paul TF. Malignant Melanoma of the
Eyelid. New York: Eye Cancer Centre;
Available from: Eyecancer.com
[4] Shields CL, Shields JA, Gunduz K, et
al. Conjunctival melanoma: risk factors
for recurrence, exenteration, metastasis,
and death in 150 consecutive patients.
Arch Ophthalmol. 2000;118(11):1497-
1507
[5] Stremnel I, Kroll P. Conjunctival
malignant melanoma in children.
Journal of Ophthalmology. 1999;213:
129-132
[6] Shields CL, Shields JA. Tumors of the
conjunctiva and cornes. Survey of
Ophthalmology. 2004;49:3-24
[7] Shields JA, Eyelid SCL. Conjunctival
and Orbital Tumors. An Atlas and
Textbook. 2nd ed. Philadelphia, PA:
Lippincott Williams and Wilkins; 2008.
pp. 250-445
[8]Honavar SG, Manjandavida FP.
Tumors of the ocular surface. A review.
Indian Journal of Ophthalmology. 2015;
63:187-203
[9] Giblin ME, Shields JA, Shields CL,
Eagle RC Jr. Primary eyelid malignant
melanoma associated with primary
conjunctival malignant melanoma.
Australian and New Zealand Journal of
Ophthalmology. 1988;16:127-131
[10] Shields CL, Demirci H, Karatza E,
Shields JA. Clinical survey of 1643
melanocytic and nonmelanocytic
conjunctival tumors. Ophthalmology.
2004;111:1747-1754
[11] Shields CL, Markowitz JS, Belinsky I,
et al. Conjunctival melanoma: Outcomes
based on tumor origin in 382 consecutive
cases. Ophthalmology. 2011;118(2):
389-395.e952. DOI: 10.1016/j.
ophtha.2010.06.021
[12] Kini A, Fu R, Compton C,
Miller DM, Ramasubramanian A.
Pembrolizumab for recurrent
conjunctival melanoma. JAMA
Ophthalmology. 2017;135(8):891-892.
DOI: 10.1001/jamaophthalmol.
2017.2279
[13] Sagiv O, Thakar SD, Kandl TJ, et al.
Immunotherapy with programmed cell
death 1 inhibitors for 5 patients with
conjunctival melanoma. JAMA
Ophthalmology. 2018;136(11):
1236-1241. DOI: 10.1001/
jamaophthalmol.2018.3488
[14] Shields CL, Kaliki S, Furuta M, et al.
Clinical spectrum and prognosis of uveal
melanoma based on age at presentation
in 8,033 cases. Retina. 2012;32(7):
1363-1372
[15]McLaughlin JP, Fung AT, Shields JA,
Shields CL. Iris melanoma in children:
Current approach to management.
Oman Journal of Ophthalmology. 2013;
6(1):53-55
[16] Shields CL, Kaliki S, Shah SU,
Luo W, Furuta M, Shields JA. Iris
melanoma: Features and prognosis in
317 children and adults. Journal of
AAPOS. 2012;16(1):6-10. 7
[17] Shields CL, Shields JA, Materin M,
Gershenbaum E, Singh AD, Smith A.
Iris melanoma: Risk factors for
metastasis in 169 consecutive
patients. Ophthalmology. 2001;108(1):
172-178
16
Melanoma
[18]Oittinen HA-L, O’Shaughnessy M,
Cullinane AB, et al. Malignant
melanoma of the ciliary body presenting
as extraocular metastasis in the
temporalis muscle. Journal of Clinical
Pathology. 2007;60:834-835
[19] Costache M et al. Ciliary body
melanoma—A particularly rare type of
ocular tumor. Case report and general
considerations. Maedica. 2013;8(4):
360-364
[20]Updated classification for primary
iris melanoma [Internet]. 2017.
Available from: https://retinatoday.c
om/articles [Accessed: 26 July 2020]
[21] Kalki S, Shields CL, Shields JA.
Uveal melanoma: Estimating prognosis.
Indian Journal of Ophthalmology. 2015;
63:93-102
[22]Diener-West M, Reynolds SM,
Agugliaro DJ, Caldwell R, Cumming K,
Earle JD, et al. Development of
metastatic disease after enrollment in
the COMS trials for treatment of
choroidal melanoma: Collaborative
Ocular Melanoma Study Group Report
No 26. Archives of Ophthalmology.
2005;123:1639-1643
[23] Zloto O, Pe’er J, Frenkel S. Gender
differences in clinical presentation and
prognosis of uveal melanoma.
Investigative Ophthalmology & Visual
Science. 2013;54:652-656
[24] Rietschel P, Panageas KS, Hanlon C,
Patel A, Abramson DH, Chapman PB.
Variates of survival in metastatic uveal
melanoma. Journal of Clinical Oncology.
2005;23:8076-8080
[25] Shields CL, Kaliki S, Furuta M,
Shields JA. Diffuse versus nondiffuse
small (=3 MM thickness) choroidal
melanoma: Comparative analysis in
1,751 cases. The 2012 F. Phinizy Calhoun
lecture. Retina. 2013;33:1763-1776
[26]Damato B. Does ocular treatment of
uveal melanoma influence survival?
British Journal of Cancer. 2010;103:
285-290
[27] Shields CL, Furuta M,
Thangappan A, et al. Metastasis of uveal
melanoma millimeter-by-millimeter in
8033 consecutive eyes. Archives of
Ophthalmology. 2009;127(8):
989-998. DOI: 10.1001/
archophthalmol.2009.208
[28] Eskelin S, Pyrhonen S,
Summanen P, Hahka-Kemppinen M,
Kivela T. Tumor doubling times in
metastatic malignant melanoma of the
uvea: Tumor progression before and
after treatment. Ophthalmology. 2000;
107(8):1443-1449. DOI: 10.1016/
s0161-6420(00)00182-2
[29] The Collaborative Ocular
Melanoma Study (COMS) randomized
trial of pre-enucleation radiation of
large choroidal melanoma, II: Initial
mortality findings. COMS report no. 10.
American Journal of Ophthalmology.
1998;125:779-796
[30]Hawkins BS, Collaborative Ocular
Melanoma Study Group. The
Collaborative Ocular Melanoma Study
(COMS) randomized trial of pre-
enucleation radiation of large choroidal
melanoma: IV. Ten-year mortality
findings and prognostic factors. COMS
report number 24. American Journal of
Ophthalmology. 2004;138:936-951
[31] Spendlove HE, Damato BE,
Humphreys J, Barker KT, Hiscott PS,
Houlston RS. BRAF mutations are
detectable in conjunctival but not
uveal melanomas. Melanoma Research.
2004;14(6):449-452. [PubMed:
15577314]
[32]Griewank KG, Westekemper H,
Murali R, et al. Conjunctival melanomas
harbor BRAF and NRAS mutations and
copy number changes similar to
cutaneous and mucosal melanomas.
Clinical Cancer Research: An Official
Journal of the American Association for
17
Ocular Melanoma
DOI: http://dx.doi.org/10.5772/intechopen.93760
Cancer Research. 2013;19(12):
3143-3152. [PubMed: 23633454]
[33] Beadling C, Jacobson-Dunlop E,
Hodi FS, et al. KIT gene mutations and
copy number in melanoma subtypes.
Clinical Cancer Research: An Official
Journal of the American Association for
Cancer Research. 2008;14(21):
6821-6828
[34] Shields CL, Ganguly A,
Bianciotto CG, Turaka K, Tavallali A,
Shields JA. Prognosis of uveal melanoma
in 500 cases using genetic testing of
fine-needle aspiration biopsy specimens.
Ophthalmology. 2011;118(2):396-401.
DOI: 10.1016/j.ophtha.2010.05.023
18
Melanoma
